

*This is a free translation of the Adocia's table of financial resolutions issued in the French language, for informational purposes only.*

**DESCRIPTIVE TABLE ON THE FINANCIAL RESOLUTIONS TO BE SUBMITTED TO  
THE COMBINED SHAREHOLDERS' MEETING OF JUNE 28, 2022 (\*)**

The table below summarizes the key elements of each of the financial resolutions to be submitted to the combined Shareholders' Meeting of Adocia (the «Company») to be held on June 28, 2022.

Resolution N°	Subject matter of the resolution	Description
15	Consultation of shareholders, pursuant to Article L. 225-248 of the French Commercial Code, on the possible early dissolution of the Company following the recognition of accounting losses that reduce shareholders' equity to less than half the share capital.	<ul style="list-style-type: none"> <li>- As a result of losses incurred during the year ended December 31, 2021, the Company's shareholders' equity has fallen below one-half of the share capital.</li> <li>- Continuation of the Company's activities.</li> </ul>
16	Authorization to be given to the Board to reduce stated capital by cancelling shares pursuant to the authorization to purchase its own shares	<ul style="list-style-type: none"> <li>- Limitation of 10% of registered capital per 24 months.</li> <li>- Validity period: 18 months.</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Renewal of the 16<sup>th</sup> resolution of the shareholders' meeting of May 20th, 2021.</li> </ul>
17	Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities, with a preemptive subscription right for shareholders	<ul style="list-style-type: none"> <li>- Total amount of stated capital increases which can be decided under this resolution: € 385 000</li> <li>- Maximum amount of debt securities giving access to registered capital that can be issued under this resolution: € 50,000,000.</li> <li>- Validity period 26 months.</li> <li>- Renewal of the 17<sup>th</sup> resolution of the shareholders' meeting of May 28th, 2020.</li> </ul>

18	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (investors active in the sector health or biotechnologies)	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 144 000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €50,000,000.</li> <li>- Within the limit of the overall ceiling provided for in the 21th resolution</li> <li>- Validity period: 18 months.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Renewal of the 20th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>
19	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (strategic or financial partners)	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 144 000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €50,000,000.</li> <li>- Within the limit of the overall ceiling provided for in the 21th resolution</li> <li>- Validity period: 18 months.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Renewal of the 20th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>
20	Delegation of authority granted to the Board of Directors to increase capital by issuing common shares with or without a preemptive subscription right for shareholders as decided in the above-mentioned resolutions,	<ul style="list-style-type: none"> <li>- Possibility to increase by 15% the number of securities to be issued in the event of a capital increase with or without DPS, within the limit of 15% of the initial increase under the above resolutions</li> <li>- Within the limit of the overall ceiling provided for in the 21th resolution</li> <li>- At the same price as the original issue and within the limit of 15% of the initial issue.</li> <li>- Validity period: 26 months.</li> <li>- Renewal of the 22th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>

21	Aggregate limits on the issues completed pursuant to the seventh to twentieth resolutions	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 385,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €50,000,000.</li> <li>- Renewal of the 25th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>
22	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities giving access to capital or giving access to securities representing receivables granting access to capital, without a preemptive subscription right for shareholders, in favor of a certain category of persons within a specific equity or bond financing program	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 144 000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €50,000,000.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Within the limit of the overall ceiling provided for in the 21th resolution</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 21th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>
23	Delegation of authority granted to the Board of Directors to issue and attribute warrants for shares, without a preemptive subscription right for shareholders, to the profit of (i) board members and advisors at the grant date of the warrants (ii) persons bound by a contract or by a consulting agreement to the Company or to any of its subsidiaries or (iii) members of a committee created or to be created by the board	<ul style="list-style-type: none"> <li>- the issue price of a warrant will be determined by the Board on the day of issue of the said warrant based on the characteristics of the warrant and will be at least equal to 15% of the volume-weighted average price of the last five (5) trading days;</li> <li>- Maximum number of shares that can be issued upon exercise of BSA: 200,000.</li> <li>- Subscription price of the share to which the BSA gives right must at least be equal to the highest value between (i) sale price of a share the day before the allocation, and (ii) the weighted average of the 20 trading sessions.</li> <li>- Validity of the BSA: 10 years</li> <li>- Validity period: 18 months.</li> <li>- within the limit of the overall ceiling provided for in the 25th resolution</li> <li>- Renewal of the 26th resolution of the shareholders' meeting of May 20, 2021.</li> </ul>

24	Authorization to consent to the board to proceed to grant free existing shares or newly - issued shares, in accordance with the provisions of Articles L. 225-197-1 and seq. of the French Commercial Code, entailing the waiver by shareholders of their preferential subscription rights	<ul style="list-style-type: none"> <li>- Maximum number of shares that can be issued upon exercise of options: 200,000.</li> <li>- Acquisition period of at least 1 year with a cumulated period of acquisition and retention not be less than 2 years.</li> <li>- Validity of the shares: 10 years</li> <li>- Within the limit of the overall ceiling provided for in the 25th resolution</li> <li>- Validity period: 38 months.</li> <li>- Renewal of the 27<sup>th</sup> resolution of the shareholders' meeting of May 16,2019.</li> </ul>
25	Aggregate limits on the amount of issues completed pursuant to the delegations mentioned above (resolutions twenty-third and twenty-fourth resolutions),	<ul style="list-style-type: none"> <li>- Maximum nominal amount of issues completed pursuant application of the twenty-third and twenty fourth resolutions: € 300,000</li> </ul>
26	Delegation to be granted to the Board to increase stated capital by issuing shares without a preemptive subscription right for shareholders in favor of the employees who participate in a corporate savings plan	<ul style="list-style-type: none"> <li>- Capital increase reserved for employees who are members of a PEE of the company.</li> <li>- Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 20,000.</li> <li>- The issue price of shares giving access to capital will be determined by the board of directors and may not be higher than the average of the prices quoted at the 20 trading sessions preceding the day of the decision of the board of directors fixing the date subscription opening period or more than 20% below this average or 30% when the unavailability period provided for by the plan is greater than or equal to 10 years</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 30<sup>th</sup> resolution of the shareholders' meeting of May 20, 2021</li> </ul>
27	Delegation to be granted to the Board to increase the maximum nominal amount of shares that may be issued upon conversion of the bonds convertible into shares known as "OC1023" issued by the Company on October 26, 2021	<ul style="list-style-type: none"> <li>- Modification of the ceiling of the 20th resolution of the General Meeting of May 20, 2021</li> <li>- Increase in the maximum nominal amount of shares that may be issued in the event of conversion of the OC1023: 150,200.80 euros instead of 126,200.80 euros</li> </ul>

